{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T01:07:04Z","timestamp":1789002424552,"version":"build-2803163510"},"reference-count":98,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.bioorg.2025.108921","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T15:16:20Z","timestamp":1756221380000},"page":"108921","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Design, synthesis, and anticancer evaluation of new Quinazoline hybrids: DNA intercalation, topoisomerase II\u03b1 inhibition, and in silico studies"],"prefix":"10.1016","volume":"164","author":[{"given":"Rasha A.","family":"Hassan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeinab","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman Abo","family":"Elmaaty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed R.","family":"Elnagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr M.","family":"Abdou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akram Hifny Abd","family":"El-Haleem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed I.A.","family":"Hamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2025.108921_bb0005","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.ebiom.2015.05.022","article-title":"Is Cancer a genetic disease or a metabolic disease?","volume":"2","author":"Wishart","year":"2015","journal-title":"EBioMedicine"},{"key":"10.1016\/j.bioorg.2025.108921_bb0010","article-title":"Variation in effects of Non-Hodgkin lymphoma risk factors according to the human leukocyte antigen (HLA)-DRB1*01:01 allele and ancestral haplotype 8.1","volume":"6","author":"Wang","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.bioorg.2025.108921_bb0015","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1100\/2011\/373876","article-title":"Human leukocyte antigen class i and II alleles and overall survival in diffuse large B-cell lymphoma and follicular lymphoma","volume":"11","author":"Lu","year":"2011","journal-title":"Sci. World J."},{"key":"10.1016\/j.bioorg.2025.108921_bb0020","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41568-020-0290-x","article-title":"A compendium of mutational cancer driver genes","volume":"20","author":"Mart\u00ednez-Jim\u00e9nez","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2025.108921_bb0025","doi-asserted-by":"crossref","first-page":"443","DOI":"10.34172\/jhp.2021.52","article-title":"Two new flavonos and anticancer activity of Hymenosporum flavum: in vitro and molecular docking studies","volume":"10","author":"Taher","year":"2021","journal-title":"J. HerbMed Pharmacol."},{"key":"10.1016\/j.bioorg.2025.108921_bb0030","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(12)70211-5","article-title":"Global cancer transitions according to the human development index (2008-2030): a population-based study","volume":"13","author":"Bray","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bioorg.2025.108921_bb0035","doi-asserted-by":"crossref","first-page":"1900113","DOI":"10.1002\/ardp.201900113","article-title":"Design, synthesis, molecular docking, and anticancer activity of benzoxazole derivatives as VEGFR-2 inhibitors","volume":"352","author":"El-Helby","year":"2019","journal-title":"Arch. Pharm. (Weinheim)."},{"key":"10.1016\/j.bioorg.2025.108921_bb0040","doi-asserted-by":"crossref","first-page":"1900178","DOI":"10.1002\/ardp.201900178","article-title":"Benzoxazole\/benzothiazole-derived VEGFR-2 inhibitors: design, synthesis, molecular docking, and anticancer evaluations","volume":"352","author":"El-Helby","year":"2019","journal-title":"Arch. Pharm. (Weinheim)."},{"key":"10.1016\/j.bioorg.2025.108921_bb0045","doi-asserted-by":"crossref","first-page":"13990","DOI":"10.1039\/D0NJ02844D","article-title":"Molecular modelling of mebendazole polymorphs as a potential colchicine binding site inhibitor","volume":"44","author":"Al-Karmalawy","year":"2020","journal-title":"New J. Chem."},{"key":"10.1016\/j.bioorg.2025.108921_bb0050","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1021\/acsptsci.0c00144","article-title":"Empagliflozin and doxorubicin synergistically inhibit the survival of triple-negative breast Cancer cells via interfering with the mTOR pathway and inhibition of calmodulin: in vitro and molecular docking studies","volume":"3","author":"Eliaa","year":"2020","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.bioorg.2025.108921_bb0055","doi-asserted-by":"crossref","first-page":"21657","DOI":"10.1039\/D1NJ02885E","article-title":"Design and synthesis of a new series of 3,5-disubstituted-1,2,4-oxadiazoles as potential colchicine binding site inhibitors: Antiproliferative activity, molecular docking, and SAR studies","volume":"45","author":"Diab","year":"2021","journal-title":"New J. Chem."},{"key":"10.1016\/j.bioorg.2025.108921_bb0060","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2021.628398","article-title":"Revisiting activity of some Nocodazole analogues as a potential anticancer drugs using molecular docking and DFT calculations","volume":"9","author":"Khattab","year":"2021","journal-title":"Front. Chem."},{"key":"10.1016\/j.bioorg.2025.108921_bb0065","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx446","article-title":"Acquired chemotherapy resistance in ovarian cancer","volume":"28","author":"Christie","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bioorg.2025.108921_bb0070","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1158\/2159-8290.CD-16-0241","article-title":"Cellular senescence promotes adverse effects of chemotherapy and cancer relapse","volume":"7","author":"Demaria","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bioorg.2025.108921_bb0075","doi-asserted-by":"crossref","first-page":"17374","DOI":"10.1039\/D0NJ04088F","article-title":"Tanshinone IIA synergistically enhances the antitumor activity of doxorubicin by interfering with the PI3K\/AKT\/mTOR pathway and inhibition of topoisomerase II:: In vitro and molecular docking studies","volume":"44","author":"Ghanem","year":"2020","journal-title":"New J. Chem."},{"key":"10.1016\/j.bioorg.2025.108921_bb0080","doi-asserted-by":"crossref","first-page":"725135","DOI":"10.3389\/fchem.2021.725135","article-title":"Design and synthesis of new Quinoxaline derivatives as potential histone deacetylase inhibitors targeting hepatocellular carcinoma: in silico, in vitro, and SAR studies","volume":"9","author":"Ma","year":"2021","journal-title":"Front. Chem."},{"key":"10.1016\/j.bioorg.2025.108921_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105861","article-title":"Novel antiproliferative agents bearing substituted thieno[2,3-d]pyrimidine scaffold as dual VEGFR-2 and BRAF kinases inhibitors and apoptosis inducers; design, synthesis and molecular docking","volume":"125","author":"Hassan","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108921_bb0090","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1080\/14756366.2021.1901089","article-title":"Design, synthesis, anticancer evaluation, and molecular modelling studies of novel tolmetin derivatives as potential VEGFR-2 inhibitors and apoptosis inducers","volume":"36","author":"Kassab","year":"2021","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108921_bb0095","doi-asserted-by":"crossref","first-page":"35321","DOI":"10.1039\/D3RA06614B","article-title":"Five and six membered heterocyclic rings endowed with azobenzene as dual EGFRT790M and VEGFR-2 inhibitors: design, synthesis, in silico ADMET profile, molecular docking, dynamic simulation and anticancer evaluations","volume":"13","author":"Anwer","year":"2023","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2025.108921_bb0100","first-page":"287","article-title":"Dual VEGFR-2 and EGFRT790M inhibitors of phenyldiazenes: anticancer evaluations, ADMET, docking, design and synthesis, future","volume":"17","author":"Alsulaimany","year":"2025","journal-title":"Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108921_bb0105","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/nrc2342","article-title":"DNA repair pathways as targets for cancer therapy","volume":"8","author":"Helleday","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2025.108921_bb0110","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.bmcl.2007.12.035","article-title":"Novel 3-alkoxy-1H-pyrazolo[3,4-d]pyrimidines as EGFR and erbB2 receptor tyrosine kinase inhibitors, bioorganic med","volume":"18","author":"Ducray","year":"2008","journal-title":"Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.108921_bb0115","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/14756366.2021.2007905","article-title":"Topo II inhibition and DNA intercalation by new phthalazine-based derivatives as potent anticancer agents: design, synthesis, anti-proliferative, docking, and in vivo studies","volume":"37","author":"Khalifa","year":"2022","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108921_bb0120","doi-asserted-by":"crossref","first-page":"627","DOI":"10.2174\/138955707780859413","article-title":"DNA intercalators in cancer therapy: organic and inorganic drugs and their spectroscopic tools of analysis","volume":"7","author":"Wheate","year":"2007","journal-title":"Mini-Rev. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108921_bb0125","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ejmech.2017.02.044","article-title":"Diphenylurea derivatives for combating methicillin- and vancomycin-resistant Staphylococcus aureus","volume":"130","author":"Eissa","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108921_bb0130","doi-asserted-by":"crossref","first-page":"10037","DOI":"10.1039\/D5RA00166H","article-title":"Design, nanogel synthesis, anti-proliferative activity and in silico ADMET profile of pyrazoles and pyrimidines as topo-II inhibitors and DNA intercalators","volume":"15","author":"Aljohani","year":"2025","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2025.108921_bb0135","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1146\/annurev.bi.58.070189.002031","article-title":"DNA topoisomerase poisons as antitumor drugs","volume":"58","author":"Liu","year":"1989","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.bioorg.2025.108921_bb0140","doi-asserted-by":"crossref","first-page":"67","DOI":"10.7326\/0003-4819-105-1-67","article-title":"Mitoxantrone: a new anticancer drug with significant clinical activity","volume":"105","author":"Shenkenberg","year":"1986","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.bioorg.2025.108921_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.103828","article-title":"Design and synthesis of 3,5-substituted 1,2,4-oxadiazoles as catalytic inhibitors of human DNA topoisomerase II\u03b1","volume":"99","author":"Loboda","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108921_bb0150","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1146\/annurev.biophys.33.110502.140357","article-title":"Structure, molecular mechanisms, and evolutionary relationships in DNA topoisomerases","volume":"33","author":"Corbett","year":"2004","journal-title":"Annu. Rev. Biophys. Biomol. Struct."},{"key":"10.1016\/j.bioorg.2025.108921_bb0155","article-title":"Thieno[2,3-d]pyrimidine derivatives as topoisomerase II inhibitors: design, synthesis, anticancer evaluation, and in silico studies","volume":"164","author":"Hassan","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108921_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104255","article-title":"Design, efficient synthesis, docking studies, and anticancer evaluation of new quinoxalines as potential intercalative topo II inhibitors and apoptosis inducers","volume":"104","author":"Abbass","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108921_bb0165","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.bioorg.2016.05.006","article-title":"Design, synthesis, molecular modeling and biological evaluation of novel 1H-pyrazolo[3,4-b]pyridine derivatives as potential anticancer agents","volume":"67","author":"Eissa","year":"2016","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108921_bb0170","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202000237","article-title":"Design and discovery of new 1,2,4-triazolo[4,3- c ]quinazolines as potential DNA intercalators and topoisomerase II inhibitors","volume":"354","author":"Alesawy","year":"2021","journal-title":"Arch. Pharm. (Weinheim)."},{"key":"10.1016\/j.bioorg.2025.108921_bb0175","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2174\/1568011054222364","article-title":"Etoposide, topoisomerase II and cancer","volume":"5","author":"Baldwin","year":"2005","journal-title":"Curr. Med. Chem. Agents."},{"key":"10.1016\/j.bioorg.2025.108921_bb0180","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1016\/j.ejmech.2010.06.013","article-title":"Design, synthesis and biological evaluation of novel quinazoline derivatives as potential antitumor agents: molecular docking study","volume":"45","author":"El-Azab","year":"2010","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108921_bb0185","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ejmech.2013.06.055","article-title":"Design and synthesis of novel quinazoline nitrogen mustard derivatives as potential therapeutic agents for cancer","volume":"67","author":"Li","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108921_bb0190","doi-asserted-by":"crossref","first-page":"316","DOI":"10.3987\/COM-15-13389","article-title":"Design, synthesis and anticancer activity of novel 2,3-and 2,4-disubstituted quinazoline and quinazolinone derivatives","volume":"92","author":"El-Hashash","year":"2016","journal-title":"Heterocycles"},{"key":"10.1016\/j.bioorg.2025.108921_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.103726","article-title":"Design and synthesis of some new 2,4,6-trisubstituted quinazoline EGFR inhibitors as targeted anticancer agents","volume":"98","author":"Allam","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108921_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106920","article-title":"Rational design and synthesis of novel quinazolinone N-acetohydrazides as type II multi-kinase inhibitors and potential anticancer agents","volume":"142","author":"Abd El-Karim","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108921_bb0205","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/ddr.22060","article-title":"Design, synthesis, anticancer, and antibacterial evaluation of some quinazolinone-based derivatives as DHFR inhibitors","volume":"84","author":"Osman","year":"2023","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.bioorg.2025.108921_bb0210","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1080\/14756366.2022.2118735","article-title":"Design and synthesis of novel quinazolinone-based derivatives as EGFR inhibitors with antitumor activity","volume":"37","author":"Sonousi","year":"2022","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108921_bb0215","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ejmech.2015.04.028","article-title":"Design, synthesis and biological evaluation of quinazoline derivatives as anti-trypanosomatid and anti-plasmodial agents","volume":"96","author":"Mendoza-Mart\u00ednez","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108921_bb0220","doi-asserted-by":"crossref","first-page":"5474","DOI":"10.1016\/j.bmcl.2009.07.081","article-title":"Design and synthesis of novel substituted quinazoline derivatives as antileishmanial agents, bioorganic med","volume":"19","author":"Agarwal","year":"2009","journal-title":"Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.108921_bb0225","first-page":"61","article-title":"New generation of Quinazolinone derivatives as potent antimicrobial agents, Asian Pacific","volume":"8","author":"Patel","year":"2021","journal-title":"J. Health Sci."},{"key":"10.1016\/j.bioorg.2025.108921_bb0230","doi-asserted-by":"crossref","first-page":"16338","DOI":"10.1021\/acsomega.8b01592","article-title":"Design and synthesis of Imidazo\/Benzimidazo[1,2- c]quinazoline derivatives and evaluation of their antimicrobial activity","volume":"3","author":"Nandwana","year":"2018","journal-title":"ACS Omega"},{"key":"10.1016\/j.bioorg.2025.108921_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108549","article-title":"Synthesis and evaluation of antibacterial activity of new thieno[2,3-d]pyrimidine hybrid compounds targeting dihydropteroate synthase to combat antibiotic resistance","volume":"161","author":"Hassan","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108921_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105127","article-title":"Design and synthesis of novel quinazolinone-pyrazole derivatives as potential \u03b1-glucosidase inhibitors: structure-activity relationship, molecular modeling and kinetic study","volume":"114","author":"Azimi","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108921_bb0245","article-title":"Design, synthesis and anti-influenza a virus activity of novel 2,4-disubstituted quinazoline derivatives","volume":"30","author":"Wang","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.108921_bb0250","doi-asserted-by":"crossref","first-page":"4413","DOI":"10.1021\/acsabm.2c00562","article-title":"Design and synthesis of quinazolinone-triazole hybrids as potent anti-tubercular agents","volume":"5","author":"Dutta","year":"2022","journal-title":"ACS Appl. Bio Mater."},{"key":"10.1016\/j.bioorg.2025.108921_bb0255","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0274081","article-title":"New [1,2,4]triazolo[4,3-c]quinazolines as intercalative topo II inhibitors: design, synthesis, biological evaluation, and in silico studies","volume":"18","author":"Gaber","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.bioorg.2025.108921_bb0260","doi-asserted-by":"crossref","first-page":"12873","DOI":"10.1021\/acs.jmedchem.0c00774","article-title":"Novel, potent, and Druglike Tetrahydroquinazoline inhibitor that is highly selective for human topoisomerase II \u03b1 over \u03b2","volume":"63","author":"Ortega","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108921_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112504","article-title":"Targeting topoisomerase II with trypthantrin derivatives: discovery of 7-((2-(dimethylamino)ethyl)amino)indolo[2,1-b]quinazoline-6,12-dione as an antiproliferative agent and to treat cancer","volume":"202","author":"Catanzaro","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108921_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115661","article-title":"Novel fused imidazotriazines acting as promising top. II inhibitors and apoptotic inducers with greater selectivity against head and neck tumors: design, synthesis, and biological assessments","volume":"259","author":"Al-Karmalawy","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108921_bb0275","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1039\/D3MD00476G","article-title":"Novel pyrazolo[3,4- d ]pyrimidine derivatives: design, synthesis, anticancer evaluation, VEGFR-2 inhibition, and antiangiogenic activity","volume":"14","author":"Abdelhamed","year":"2023","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108921_bb0280","doi-asserted-by":"crossref","DOI":"10.1002\/ddr.70007","article-title":"New S -substituted-3-phenyltetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one scaffold with promising anticancer activity profile through the regulation and inhibition of mutated B-RAF signaling pathway","volume":"85","author":"Seif","year":"2024","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.bioorg.2025.108921_bb0285","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/ddr.22058","article-title":"Design and synthesis of novel hexahydrobenzo[4,5]thieno[2,3-d]pyrimidine derivatives as potential anticancer agents with antiangiogenic activity via VEGFR-2 inhibition, and down-regulation of PI3K\/AKT\/mTOR signaling pathway","volume":"84","author":"Seif","year":"2023","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.bioorg.2025.108921_bb0290","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/ddr.22088","article-title":"Design, synthesis, anticancer evaluation, and in silico studies of some thieno[2,3- d ]pyrimidine derivatives as EGFR inhibitors","volume":"84","author":"Sayed","year":"2023","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.bioorg.2025.108921_bb0295","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1039\/D5MD00139K","article-title":"Novel furo[2,3- d ]pyrimidine derivatives as PI3K\/AKT dual inhibitors: design, synthesis, biological evaluation, and molecular dynamics simulation","volume":"16","author":"Reheim","year":"2025","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108921_bb0300","first-page":"1219","article-title":"Thiazolation of phenylthiosemicarbazone to access new thiazoles\u00a0: anticancer activity and molecular docking, future","volume":"16","author":"Elgammal","year":"2024","journal-title":"Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108921_bb0305","doi-asserted-by":"crossref","DOI":"10.1002\/cbdv.202400077","article-title":"Design, synthesis, and molecular docking of novel miscellaneous Chalcones as p38\u03b1 mitogen-activated protein kinase inhibitors","volume":"21","author":"Zeid","year":"2024","journal-title":"Chem. Biodivers."},{"key":"10.1016\/j.bioorg.2025.108921_bb0310","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1039\/D4MD00462K","article-title":"Design, synthesis, and biological evaluation of novel thiazole derivatives as PI3K\/mTOR dual inhibitors","volume":"15","author":"Faggal","year":"2024","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108921_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2025.118286","article-title":"Design, synthesis, and anticancer evaluation of new pyrazolo[3,4-d]pyrimidine-based derivatives: CDK2 inhibition, apoptosis-inducing activity, molecular modelling studies","volume":"128","author":"Hassan","year":"2025","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108921_bb0320","doi-asserted-by":"crossref","first-page":"30346","DOI":"10.1039\/D4RA04036H","article-title":"Design, synthesis, biological evaluation, and docking studies of novel triazolo[4,3- b ]pyridazine derivatives as dual c-met\/Pim-1 potential inhibitors with antitumor activity","volume":"14","author":"Mahmoud","year":"2024","journal-title":"RSC Adv."},{"issue":"2","key":"10.1016\/j.bioorg.2025.108921_bb0325","first-page":"2909","article-title":"Reactions of 2-methyl-3,1-benzoxazin-4-one with active methylene compounds: a new route to 3-substituted 4-hydroxyquinoline-2(1H)-ones","volume":"1","author":"Collins","year":"1996","journal-title":"J. Chem. Soc. Perkin Trans."},{"key":"10.1016\/j.bioorg.2025.108921_bb0330","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.ejmech.2014.09.028","article-title":"Development of 2-(4-oxoquinazolin-3(4 H)-yl)acetamide derivatives as novel enoyl-acyl carrier protein reductase (InhA) inhibitors for the treatment of tuberculosis","volume":"86","author":"Pedgaonkar","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108921_bb0335","first-page":"4723","article-title":"Design, synthesis, molecular modeling and anti-hyperglycemic evaluation of quinazolin-4(3H)-one derivatives as potential PPAR\u03b3 and SUR agonists, bioorganic","volume":"25","author":"Ibrahim","year":"2017","journal-title":"Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108921_bb0340","first-page":"770","article-title":"Srinivas; Rao, synthesis and antimicrobial activity of some pyrazoline derivatives of 4(3H)-quinazolinones","volume":"79","author":"Panda","year":"2002","journal-title":"J. Indian Chem. Soc."},{"key":"10.1016\/j.bioorg.2025.108921_bb0345","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ddr.430340203","article-title":"Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen","volume":"34","author":"Boyd","year":"1995","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.bioorg.2025.108921_bb0350","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nrc1951","article-title":"The NCI60 human tumour cell line anticancer drug screen","volume":"6","author":"Shoemaker","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2025.108921_bb0355","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1093\/jnci\/82.13.1107","article-title":"New colorimetric cytotoxicity assay for anticancer-drug screening","volume":"82","author":"Skehan","year":"1990","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.bioorg.2025.108921_bb0360","first-page":"589","article-title":"Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay","volume":"48","author":"Alley","year":"1988","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108921_bb0365","first-page":"6475","article-title":"Synthesis and in vitro antitumor evaluation of some indeno[1,2-c]pyrazol(in)es substituted with sulfonamide, sulfonylurea(\u2212thiourea) pharmacophores, and some derived thiazole ring systems, bioorganic","volume":"14","author":"Rostom","year":"2006","journal-title":"Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108921_bb0370","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1021\/np50089a004","article-title":"A colorimetric microassay for the detection of agents that interact with DNA","volume":"55","author":"Burres","year":"1992","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.bioorg.2025.108921_bb0375","first-page":"525","article-title":"Protective effects of Mirazid on gentamicin-induced nephrotoxicity in rats through antioxidant, anti-inflammatory, JNK1\/ iNOS, and apoptotic pathways; novel mechanistic insights","volume":"28","author":"Antar","year":"2022","journal-title":"Pharm. Sci."},{"key":"10.1016\/j.bioorg.2025.108921_bb0380","doi-asserted-by":"crossref","first-page":"31339","DOI":"10.1039\/D1RA05817G","article-title":"Investigating the structure-activity relationship of marine natural polyketides as promising SARS-CoV-2 main protease inhibitors","volume":"11","author":"El-Demerdash","year":"2021","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2025.108921_bb0385","doi-asserted-by":"crossref","first-page":"29267","DOI":"10.1039\/D1RA05268C","article-title":"Anti-SARS-CoV-2 activities of tanshinone IIA, carnosic acid, rosmarinic acid, salvianolic acid, baicalein, and glycyrrhetinic acid between computational andin vitroinsights","volume":"11","author":"Elebeedy","year":"2021","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2025.108921_bb0390","doi-asserted-by":"crossref","first-page":"10027","DOI":"10.1039\/D0RA10674G","article-title":"Revisiting activity of some glucocorticoids as a potential inhibitor of SARS-CoV-2 main protease: theoretical study","volume":"11","author":"Elmaaty","year":"2021","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2025.108921_bb0395","first-page":"1623","article-title":"Computational repurposing of benzimidazole anthelmintic drugs as potential colchicine binding site inhibitors, future","volume":"13","author":"Khattab","year":"2021","journal-title":"Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108921_bb0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.imu.2022.100869","article-title":"Rumex Vesicarius L. extract improves the efficacy of doxorubicin in triple-negative breast cancer through inhibiting Bcl2, mTOR, JNK1 and augmenting p21 expression","volume":"29","author":"Ghanem","year":"2022","journal-title":"Informatics Med. Unlocked."},{"key":"10.1016\/j.bioorg.2025.108921_bb0405","doi-asserted-by":"crossref","first-page":"10861","DOI":"10.1093\/nar\/gkx742","article-title":"Producing irreversible topoisomerase II-mediated DNA breaks by site-specific Pt(II)-methionine coordination chemistry","volume":"45","author":"Wang","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bioorg.2025.108921_bb0410","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0114904","article-title":"Novel DNA topoisomerase II\u03b1 inhibitors from combined ligand- and structure-based virtual screening","volume":"9","author":"Drwal","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.bioorg.2025.108921_bb0415","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1021\/acs.jcim.9b00605","article-title":"Smoothed potential MD simulations for dissociation kinetics of etoposide to unravel isoform specificity in targeting human topoisomerase II","volume":"59","author":"Kuriappan","year":"2019","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.bioorg.2025.108921_bb0420","doi-asserted-by":"crossref","first-page":"072","DOI":"10.30574\/gscbps.2021.15.2.0099","article-title":"Virtual high-throughput screening (VHTS), three-dimensional quantitative structure- activity and relationship (3D-QSAR) and molecular docking studies of novel phyto-inhibtors of topoisomerase II alpha","volume":"15","author":"Adeniran","year":"2021","journal-title":"GSC Biol. Pharm. Sci."},{"key":"10.1016\/j.bioorg.2025.108921_bb0425","first-page":"1","article-title":"1st Int. Conf. Heal. Sci. Technol","volume":"2023","author":"H.N. Nguyen, H.M. Pham Thi, H. Luu van, T.H. Le Thi, M.Q. Pham, H.T. Dao, An in Silico Study: Searching for Potential Anti-Cancer Agents from Xanthone Derivatives Targeting Topoisomerase II-Alpha Protein, in","year":"2023","journal-title":"IEEE"},{"key":"10.1016\/j.bioorg.2025.108921_bb0430","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0753-3322(02)00205-6","article-title":"Integrated communications and navigation module","volume":"56","author":"Scalbert","year":"2002","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bioorg.2025.108921_bb0435","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0169-409X(01)00231-9","article-title":"Oral drug absorption enhancement by chitosan and its derivatives","volume":"52","author":"Thanou","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bioorg.2025.108921_bb0440","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(96)00423-1","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"23","author":"Lipinski","year":"1997","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bioorg.2025.108921_bb0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108746","article-title":"ADMET, docking, anticancer evaluations, design and synthesis of pyrazolo[1,5-a]pyrimidines substituted with furan and phenyldiazene as dual EGFRT790M and VEGFR-2 inhibitors","volume":"163","author":"Alsulaimany","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108921_bb0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.mrgentox.2019.07.004","article-title":"Recommended criteria for the evaluation of bacterial mutagenicity data (Ames test)","volume":"848","author":"Levy","year":"2019","journal-title":"Mutat. Res. Genet. Toxicol. Environ. Mutagen."},{"key":"10.1016\/j.bioorg.2025.108921_bb0455","doi-asserted-by":"crossref","first-page":"4289","DOI":"10.1074\/jbc.RA117.000432","article-title":"Fluid flow modulates electrical activity in cardiac hERG potassium channels","volume":"293","author":"Roy","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2025.108921_bb0460","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.coph.2013.11.006","article-title":"HERG1 channel agonists and cardiac arrhythmia Michael","volume":"15","author":"Sanguinetti","year":"2014","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.108921_bb0465","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202100412","article-title":"Design, synthesis, in silico ADMET, docking, and antiproliferative evaluations of [1,2,4]triazolo[4,3- c]quinazolines as classical DNA intercalators","volume":"355","author":"Alesawy","year":"2022","journal-title":"Arch. Pharm. (Weinheim)."},{"key":"10.1016\/j.bioorg.2025.108921_bb0470","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/iub.1188","article-title":"Caffeic acid phenethyl ester synergistically enhances docetaxel and paclitaxel cytotoxicity in prostate cancer cells","volume":"65","author":"Tolba","year":"2013","journal-title":"IUBMB Life"},{"key":"10.1016\/j.bioorg.2025.108921_bb0475","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.3390\/plants11172192","article-title":"Potential apoptotic activities of Hylocereus undatus Peel and pulp extracts in MCF-7 and Caco-2 Cancer cell lines","volume":"11","author":"Salam","year":"2022","journal-title":"Plants"},{"key":"10.1016\/j.bioorg.2025.108921_bb0480","article-title":"Modified annexin V\/propidium iodide apoptosis assay for accurate assessment of cell death","volume":"50","author":"Rieger","year":"2011","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.bioorg.2025.108921_bb0485","doi-asserted-by":"crossref","first-page":"42717","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2025.108921_bb0490","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1021\/acs.jmedchem.5b00104","article-title":"pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures","volume":"58","author":"Pires","year":"2015","journal-title":"J. Med. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825008016?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825008016?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T05:51:52Z","timestamp":1757656312000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825008016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":98,"alternative-id":["S0045206825008016"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108921","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and anticancer evaluation of new Quinazoline hybrids: DNA intercalation, topoisomerase II\u03b1 inhibition, and in silico studies","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108921","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108921"}}